This paper is in the following e-collection/theme issue:

RCTs - Pilots/Feasibility Studies (non-eHealth) (51) Nephrology/Renal Disorders (105) Chemotherapy and Side Effects Management (118) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (223) Clinical Cancer Research (124)

Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/87907, first published .
Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial

Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial

Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial

Authors of this article:

Takenao Koseki1, 2, 3 Author Orcid Image ;   Masashi Kondo4, 5 Author Orcid Image ;   Hidetsugu Fujigaki6 Author Orcid Image ;   Kayoko Kikuchi7 Author Orcid Image ;   Yuko Oya4 Author Orcid Image ;   Hiroshi Kato5 Author Orcid Image ;   Tomohiro Mizuno1, 3 Author Orcid Image ;   Naotake Tsuboi8 Author Orcid Image ;   Kenji Kawada9 Author Orcid Image ;   Yasuhiro Goto4 Author Orcid Image ;   Naozumi Hashimoto4 Author Orcid Image ;   Kazuyoshi Imaizumi4 Author Orcid Image ;   Akiko Kada7 Author Orcid Image ;   Hikaru Yabuuchi10 Author Orcid Image ;   Kuniaki Saito6, 10 Author Orcid Image ;   Hideyuki Saya11 Author Orcid Image
Article Authors Cited by Tweetations Metrics

There are no citations yet available for this article according to Crossref .